All the data presented here highlight the feasibility and significance of KDM5A as a therapeutic target for KDM5A-overexpressing breast cancer and demonstrate that 1 could function as a new motif for the generation of more selective and effcacious pharmacological candidates against KDM5A-overexpressing cancers. This evidence concerns the gene KDM5A and breast cancer.